A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias

• Status: WITHDRAWN
• Trial end date: 2025-07-31

Summary

To find the recommended dose of the drug combination cladribine, cytarabine, decitabine, and sorafenib in participants with relapsed/refractory AML, MPAL, and ALAL.

• Phase: PHASE1

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Treatments: Cladribine; Cytarabine; Decitabine; Sorafenib